Trials / Unknown
UnknownNCT05031949
Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma
A Single-center, Single-arm, Non-randomized Clinical Study to Evaluate the Efficacy and Safety of Hyperbaric Oxygen Therapy Plus Camrelizumab as a Second-line Treatment in Advanced/Metastatic Hepatocellular Carcinoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Zhang Bi Xiang, MD · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | hyperbaric oxygen therapy plus Camrelizumab | Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody |
Timeline
- Start date
- 2021-10-30
- Primary completion
- 2024-12-31
- Completion
- 2025-06-30
- First posted
- 2021-09-02
- Last updated
- 2023-12-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05031949. Inclusion in this directory is not an endorsement.